Cerveau Technologies, Inc.   Report issue

For profit Phase 2
Founded: Boston MA United States (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2019
NCT03919669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cerveau Technologies, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

mk-6240 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1